Drugs / Nizaracianine Triflutate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06101745 Comparator | Jun 2024 → Jul 2026 overdue | ureteral disorder | Curadel Surgical Innovations, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nizaracianine Triflutate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06101745 ↗ |
| Modality | Small molecule | “Nizaracianine Triflutate (ZW800-1) is a novel small molecule drug with a unique zwitterionic chemical structure.” NCT06101745 ↗ |
| Route | Intravenous | “Participants will receive up to 3 intravenous bolus injections with a minimal interval between doses of 60 minutes (surgeon discretion).” NCT06101745 ↗ |